Rothman Joel
Known title: Chief Development OfficerCIK: 0001842921
Associated companies
Transaction History
| EQ | ▲ Buy | Grant | 8,804 | $5K | 12/8/2023 | View on chart |
| EQ | ▲ Buy | Grant | 15,000 | $8K | 6/9/2023 | View on chart |
| EQ | ▲ Buy | Grant | 3,821 | $5K | 12/9/2022 | View on chart |
| EQ | ▲ Buy | Grant | 6,244 | $12K | 6/10/2022 | View on chart |
| EQ | ▲ Buy | Grant | 1,290 | $3K | 12/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Equillium Targets Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium announced plans to start Phase I trials for its ulcerative colitis drug EQ504 in Q4. This milestone could affect the company’s future revenue if the trial is successful. The announcement comes while the stock trades near its 13‑touch support level at $2.20 and has a low RSI of 30.5.
Equillium Targets Q4 Phase I Start for Ulcerative Colitis Drug EQ504. Equillium announced plans to start Phase I trials for its ulcerative colitis drug EQ504 in Q4. This milestone could affect the company’s future revenue if the trial is successful. The announcement comes while the stock trades near its 13‑touch support level at $2.20 and has a low RSI of 30.5.